Skip to Content

Beleodaq Approval History

FDA Approved: Yes (First approved July 3, 2014)
Brand name: Beleodaq
Generic name: belinostat
Dosage form: Injection
Company: Spectrum Pharmaceuticals, Inc.
Treatment for: Peripheral T-cell Lymphoma

Beleodaq (belinostat) is a histone deacetylase (HDAC) inhibitor for the treatment of peripheral T-cell lymphoma (PTCL).

Development History and FDA Approval Process for Beleodaq

DateArticle
Jul  3, 2014Approval FDA Approves Beleodaq (belinostat) for Peripheral T-Cell Lymphoma
Feb  6, 2014Spectrum Pharmaceuticals Announces FDA's Acceptance of NDA Filing for Beleodaq (belinostat) for Injection, a novel pan-HDAC inhibitor
Dec 10, 2013New Drug Application for Belinostat in Relapsed or Refractory PTCL Submitted to the FDA

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide